Scarlet Therapeutics Ltd

Scarlet Therapeutics Ltd

Biotechnology Research

We believe the future of medicine is in our blood.

About us

Scarlet Therapeutics is developing a unique platform that generates novel red blood cell-based therapeutics to potentially treat a wide range of diseases. Initially targeted at the rare metabolic diseases, hyperammonemia and hyperoxaluria, this approach could also be used more broadly to target other metabolic diseases, cancer and autoimmune diseases. These therapeutic red blood cells (tRBCs) are very similar to standard red blood cells, having many unique qualities compared to systemic administration of therapeutic protein, including pervasive reach throughout the body, a long life and the ability to carry the active proteins within the tRBC, thereby shielding them from the immune system. Born out of more than a decade of research at the University of Bristol and its learnings from the RESTORE clinical study, Scarlet also has an exclusive commercial licence for the widely used BEL-A cell line, which provides an alternative platform technology for production of red blood cells.

Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
Bristol
Type
Privately Held
Founded
2022

Locations

Employees at Scarlet Therapeutics Ltd

Updates

Similar pages

Funding

Scarlet Therapeutics Ltd 1 total round

Last Round

Seed

Investors

SCVC
See more info on crunchbase